Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 18/11/2019 Messung_Immunantwort_Elispot2_Kopie.jpg

    Researchers successfully rejuvenate the immune system in animal models

    It is well known that stem cells age. Even the human immune system loses its power with age. Since all immune cells are derived from blood-forming stem cells, it is quite natural to associate the weakening of the immune system (immune senescence) with the ageing of blood-forming stem cells. Stem cell researchers and immunologists from the University of Ulm have now demonstrated the important role that blood-forming cells play in the ageing of the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/Researchers-successfully-rejuvenate-the-immune-system-in-animal-models
  • Article - 24/09/2019 Curevac_Franz-Werner_Haas_.png

    Neglected tropical diseases – Franz-Werner Haas: the role of technology and pharmaceutical companies

    Neglected tropical diseases (NTDs) are poverty-related infectious diseases that suffer from scant attention in terms of research or control. NTDs exist in the shadow of the "big three": malaria, tuberculosis and HIV/AIDS. They affect many people living in poverty in the emerging and developing countries of the tropics and subtropics. Active control can only be achieved when people with NTDs are treated effectively and given information…

    https://www.gesundheitsindustrie-bw.de/en/article/news/vernachlaessigte-tropenkrankheiten-franz-werner-haas-die-rolle-von-technologie-und-pharmaunternehmen
  • Article - 11/06/2019 ZurHausen.jpg

    New pathogens in beef and cow's milk contributing to the risk of cancer

    A team of researchers led by Nobel laureate Prof. Dr. med. Dr. h.c. mult. Harald zur Hausen has discovered a new type of infectious agent in dairy and meat products produced from European cattle that increases the risk for colon and breast cancer. These so-called Bovine Meat and Milk Factors (BMMFs) are small DNA molecules that are similar in sequence to both bacterial plasmids and certain viruses.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-pathogens-in-beef-and-cows-milk-contributing-to-the-risk-of-cancer
  • Article - 11/04/2019 Carsten_Koehler_Profilbild_Tropenkrankheiten_Tuebingen.jpg

    Neglected tropical diseases – Carsten Köhler: impulses from Baden-Württemberg

    More than one billion people worldwide suffer from neglected tropical diseases (NTDs). NTDs are mostly poverty-related infectious diseases that prevail in tropical countries due to lack of research and measures to detect, prevent and control them. Dr. Dr. Carsten Köhler reports on the political, economic and scientific contributions Germany and Baden-Württemberg can make to successfully change this situation.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vernachlaessigte-tropenkrankheiten-carsten-koehler-impulse-aus-baden-wuerttemberg
  • Event - 02/07/2019 Teaser_Meet_Match.jpg

    Meet & Match: Precision Medicine – Research, Diagnostics & Therapy

    Stuttgart, Registration deadline: 01/07/2019, Meet & Match
    https://www.gesundheitsindustrie-bw.de/en/event/meet-match-precision-medicine
  • Article - 18/03/2019 European Union flag in the wind.

    EHR and PHR: digital records in the German healthcare system

    EHRs, i.e. electronic health records (German: Patientenakte, ePA), are hailed as the key to increasing the quality of care. The Appointment Service and Supply Act (TSVG), adopted on 14th March 2019, requires the German statutory health insurance funds to provide policyholders with electronic health records from 1st January 2021 onwards.

    https://www.gesundheitsindustrie-bw.de/en/article/news/ehr-and-phr-digital-records-in-the-german-healthcare-system
  • Article - 05/03/2019 Schematic showing EBV particles in a blood vessel.

    Vaccination against oncogenic Epstein-Barr viruses

    Almost all humans are infected with Epstein-Barr viruses (EBV), which are linked to the development of benign diseases such as infectious mononucleosis as well as several cancers. Scientists from the German Cancer Research Center have developed a new strategy for creating a vaccine that targets different EBV virus life phases and has the potential to provide effective protection against EBV infection.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vaccination-against-oncogenic-epstein-barr-viruses
  • Article - 19/11/2018 Teaser_Nicotiana_tabacum_001.png

    Tobacco for health

    Plants can be used as biofactories to produce valuable active ingredients such as proteins, antibodies, dyes or vaccines. A project called Newcotiana aims to re-position the existent tobacco industry infrastructure. The project partners, including Prof. Dr. Holger Puchta from the Karlsruhe Institute of Technology, use modern breeding methods to develop tobacco varieties with new capabilities.

    https://www.gesundheitsindustrie-bw.de/en/article/news/tobacco-for-health
  • Article - 17/10/2018 Porträtfoto von Dr. Ralf Schumacher

    Biologicals are becoming increasingly important to Boehringer Ingelheim

    Biopharmaceuticals are playing an increasingly important role in Boehringer Ingelheim’s development pipeline. Visible evidence of this is the company’s Biologicals Development Centre (BDC) that is currently being constructed in Boehringer Ingelheim’s Biberach plant and will bring the company’s process development under one roof by early 2020. Walter Pytlik from BIOPRO talked with Dr. Ing. Ralf Schumacher about the new centre.

    https://www.gesundheitsindustrie-bw.de/en/article/news/biologicals-are-becoming-increasingly-important-to-boehringer-ingelheim
  • Article - 06/09/2018 Schematic showing the so-called breakthrough event as well as the expansion and invasion stages of cells during carcinogenesis.

    The immunogenicity of tumours and the development of new cancer medicines

    Microsatellite-unstable cancers are characterised by a large number of mutations within short repetitive DNA sequence regions, and can form novel peptides that the human immune system recognises as neoantigens. These cancers represent a starting point for the development of vaccines to prevent them appearing at an early stage of development. Microsatellite instability is particularly frequent in colon and cervical cancers.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-immunogenicity-of-tumours-and-the-development-of-new-cancer-medicines
  • Article - 25/04/2018 Prevalence of malaria in Africa.

    Resistance, immunity and malaria vaccination

    People who have survived a malaria infection often develop immunity to the disease. International malaria research is aimed at exploiting a person's natural immunity in order to treat malaria effectively and avoid resistance to previously effective drugs. These new approaches also raise hopes that one day countries at high risk of malaria may be able to eradicate the devastating disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/resistance-immunity-and-malaria-vaccination
  • Article - 14/03/2018 Bild1_Prof.KnebelDoeberitz.jpg

    Patent versus publication: setting up start-ups in the sciences

    When it comes to universities as start-up incubators, the Massachusetts Institute of Technology (MIT) in the USA is often used as a prime example of entrepreneurial impact. Well over 100 high-tech spin-offs have been set up in the vicinity of the renowned university. Many German universities also offer attractive conditions for scientists with an entrepreneurial spirit.

    https://www.gesundheitsindustrie-bw.de/en/article/news/patent-versus-publication-setting-up-start-ups-in-the-sciences
  • Article - 20/02/2018 Anopheles mosquito biting the skin.

    New strategies against malaria

    Malaria, which is a mosquito-borne disease caused by Plasmodium parasites, is still one of the worst infectious human diseases. The parasites have developed resistance against previously effective drugs and new strategies to combat malaria are urgently needed.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-strategies-against-malaria
  • Press release - 13/02/2018

    CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria

    Extends ongoing collaboration with Bill & Melinda Gates Foundation with award of two new grants. CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced the awarding of two new grants from the Bill & Melinda Gates Foundation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-entwickelt-innovative-mrna-impfstoffe-gegen-influenza-und-malaria
  • Press release - 04/01/2018

    CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics

    CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-arcturus-therapeutics-announce-broad-strategic-collaboration-to-advance-next-generation-of-lipid-mediated-mrna-thera
  • Press release - 30/10/2017 07777_de.jpg

    CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-groundbreaking-of-industrial-scale-gmp-production-facility-for-rna-therapeutics
  • Article - 22/08/2017 Two microscope images of fibroblasts of an transgenic mouse carrying the MxA gene. On the right: fibroblast nuclei. On the left: Alpha interferon treatment triggers MxA protein production. These proteins are now located around the cell nuclei.

    Transgenic mice in influenza research – risk assessment and vaccine development

    A research team from Freiburg is developing a method for identifying human influenza viruses of animal origin. This could potentially improve measures taken to prevent imminent pandemics. The researchers are working with genetically modified mice. Transgenic mice also play a role in the development of a ’universal’ influenza vaccine.

    https://www.gesundheitsindustrie-bw.de/en/article/news/transgenic-mice-in-influenza-research-risk-assessment-and-vaccine-development
  • Article - 26/06/2017 The photo shows an injection vial containing the mRNA vaccine.

    Hope for mRNA vaccines despite damper

    The pressure is on to develop novel vaccines based on messenger RNA and aimed at combating cancer and protecting against pandemics. Although mRNA vaccination as a cancer monotherapy has suffered a setback this year, the industry is nevertheless confident that it will succeed because of existing proof that mRNA vaccines stimulate the body's immune defence.

    https://www.gesundheitsindustrie-bw.de/en/article/news/hope-for-mrna-vaccines-despite-damper
  • Article - 01/06/2017 Woman in a blue lab coat pipetting a blue liquid into an electrophoresis system.

    Biotechnology – key technology of the 21st century

    According to a study published by the German National Academy of Science and Engineering (acatech) on 5th April, biotechnology is a key technology of the 21st century and has huge innovation potential. What are the trends within the industry and what are the challenges we face?

    https://www.gesundheitsindustrie-bw.de/en/article/news/biotechnology-key-technology-of-the-21st-century
  • Article - 01/06/2017 All stages of Ixodes ricinus (castor bean tick): larva (around 0.5 mm), nymph (around 1.5 mm), males (2.5 – 3.5 mm), females (3.5 – 4.5 mm)

    New TBE transmission pathways discovered

    Researchers have discovered two new TBE transmission pathways: the first related to the consumption of raw milk and raw milk cheese that can cause encephalitis, and the second is another tick species that can pass on the TBE virus, thus increasing the risk of contracting the disease even in winter.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-tbe-transmission-pathways-discovered
  • Overview

    European Immunization Week

    From 24 till 30 April 2017 is "European Immunization Week" – the BIOPRO provides information about this topic. Influenza pandemics are dangerous and can claim many lives. Children and the elderly in particular run a high risk of developing influenza-related complications, because their immune system is often weakened by the virus. In Germany, annual vaccination against seasonal influenza has therefore been recommended for these target…

    https://www.gesundheitsindustrie-bw.de/en/article/news/european-immunization-week
  • Article - 19/04/2017 View of a laboratory work place with a broad range of laboratory utensils in which a person (on the left, wearing a white lab coat) is working with frozen samples.

    Are start-ups a matter for the boss? A professor’s thoughts on university spin-offs

    Research work and entrepreneurship are by no means mutually exclusive. There are numerous successful university spin-offs in the life sciences sector that prove this only too well. However, the road from a good idea to a commercially successful company can be long and arduous. Those who benefit from the support of their boss from the outset can consider themselves extremely fortunate. Prof. Dr. Hans-Georg Rammensee talks about his experience with…

    https://www.gesundheitsindustrie-bw.de/en/article/news/are-start-ups-a-matter-for-the-boss-a-professors-thoughts-on-university-spin-offs
  • Press release - 30/11/2016

    Takeda to invest more than 100 Million Euros in Dengue Vaccine Manufacturing plant in Germany

    Konstanz, Germany, November 29, 2016 and Osaka, Japan, November 30, 2016 – Takeda Pharmaceuticals Company Limited, (“Takeda”) today announced that it will invest more than 100 Million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/takeda-to-invest-more-than-100-million-euros-in-dengue-vaccine-manufacturing-plant-in-germany
  • Press release - 04/11/2016

    Atriva Therapeutics Announces Upcoming US Patent Issuance for MEK Treatment against Viral Diseases

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-therapeutics-announces-upcoming-us-patent-issuance-for-mek-treatment-against-viral-diseases
  • Article - 20/09/2016 Prof. Dr. Anita Marchfelder, spokesperson and coordinator of the DFG research group FOR1680.

    CRISPR-Cas has more surprises in store

    Since 2012, a DFG-funded research group called FOR1680 has been studying CRISPR-Cas, an immune system that unicellular bacteria and arachaea use to protect themselves against attacks from viruses and plasmids. Prof. Dr. Anita Marchfelder, a molecular biologist at Ulm University and coordinator of the FOR1680 research group, and many other researchers were surprised to find that prokaryotes incorporate the genetic material of enemies as a kind of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/crispr-cas-has-more-surprises-in-store

Page 1 / 7

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • eine Seite zurück
  • Extend search to all portals
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2019 BIOPRO Baden-Württemberg
Website address: https://www.gesundheitsindustrie-bw.de/en/search